(917) 310-3371
Document MASH
The clinician should review how the diagnosis was established and whether another liver disease has been excluded.
Metabolic and liver care | New York
Wegovy for MASH evaluation and coordination
A narrow liver-indication page for adults with documented noncirrhotic MASH and moderate-to-advanced fibrosis, not a general fatty-liver or weight-loss page.
Start with evaluation, not a product assumption
The care team must confirm clinical fit, current records, monitoring, access, and the correct site before treatment moves forward.
Direct answer
Wegovy injection is FDA approved under the accelerated approval pathway for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis, or MASH, and moderate-to-advanced liver fibrosis consistent with stages F2 to F3. The indication does not apply to oral Wegovy, simple fatty liver without the labeled disease and fibrosis, or cirrhosis. Diagnosis and monitoring require liver-focused evaluation and often specialist coordination.
Current product and service status
This pathway applies only to adults with documented noncirrhotic MASH and F2 to F3 fibrosis. Other fatty-liver findings require their own diagnostic and treatment plan.
Confirm the labeled liver condition
MASH is not established by body weight, liver enzymes, or an ultrasound finding alone.
Document fibrosis stage
The current label is for moderate-to-advanced F2 to F3 fibrosis in adults without cirrhosis.
Review liver status
Possible cirrhosis, decompensation, significant alcohol exposure, viral hepatitis, or another complex condition needs appropriate hepatology evaluation.
Coordinate the complete plan
Medication should sit inside longitudinal liver and cardiometabolic care.
Liver-specialist input
Confirm who owns staging, surveillance, treatment monitoring, and management of other liver risks.
Metabolic treatment
Address weight, diabetes, blood pressure, cholesterol, nutrition, activity, and medicines that affect liver or metabolic health.
Wegovy safety
Review contraindications, gastrointestinal and gallbladder concerns, pancreatitis symptoms, kidney risk from dehydration, diabetes eye history, pregnancy, and procedure plans.
Understand accelerated approval
The approval is based on improvement in MASH and fibrosis while a confirmatory trial continues.
Current evidence boundary
The label states that continued approval may depend on verification and description of clinical benefit in a confirmatory trial.
Injection only
The recommended MASH maintenance regimen is Wegovy injection. The tablet does not carry the MASH indication.
No guaranteed prescription
The clinical and operational review may instead lead to more diagnostic work, hepatology care, another treatment, or no medication change.
How the evaluation moves forward
The sequence protects safety and keeps a product request from bypassing diagnosis, records, monitoring, access, or referral needs.
Bring liver records
Bring pathology, elastography, imaging, laboratory trends, hepatology notes, medication lists, and documentation of the MASH diagnosis and fibrosis stage.
Confirm label fit and exclusions
The clinician reviews noncirrhotic status, F2 to F3 fibrosis, other liver causes, safety, current treatment, and whether specialist ownership is established.
Coordinate prescribing and monitoring
If treatment is appropriate, the plan identifies who prescribes, obtains coverage, provides injection teaching, and monitors liver and medication outcomes.
Maintain long-term follow-up
The liver and metabolic teams should reassess safety, response, weight, diabetes, lipids, blood pressure, and evidence of progression.
Evaluation locations across New York
Choose a nearby Nao Medical clinic as a starting point for evaluation or care coordination.
Capability boundary: these location cards do not establish that a medicine, device, laboratory test, injection, or specialty workflow is available at every site. Confirm the exact service before travel.
Bronx
174th Street
932 E 174th St, Bronx, NY 10460
A place to begin evaluation and care coordination near West Farms, Crotona Park East, and nearby Bronx neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
Astoria
37-15 23rd Ave, Astoria, NY 11105
A place to begin evaluation and care coordination near Astoria, Ditmars, East Elmhurst, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Bronx
Bartow Mall
2063A Bartow Ave, Bronx, NY 10475
A place to begin evaluation and care coordination near Co-op City, Pelham Bay, Baychester, and nearby Bronx neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Brooklyn
Crown Heights
341 Eastern Pkwy, Brooklyn, NY 11216
A place to begin evaluation and care coordination near Crown Heights, Prospect Heights, and nearby Brooklyn neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Long Island
Hicksville
232 W Old Country Rd, Hicksville, NY 11801
A place to begin evaluation and care coordination near Hicksville, Plainview, Bethpage, and nearby Nassau County communities. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
Jackson Heights
80-10 Northern Blvd, Jackson Heights, NY 11372
A place to begin evaluation and care coordination near Jackson Heights, Elmhurst, Corona, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
Jamaica
90-18 Sutphin Blvd, Jamaica, NY 11435
A place to begin evaluation and care coordination near Jamaica, Briarwood, Richmond Hill, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
Long Island City
30-07 36th Ave, Astoria, NY 11106
A place to begin evaluation and care coordination near Long Island City, Astoria, Sunnyside, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Long Island
Mineola
135 Mineola Blvd, Mineola, NY 11501
A place to begin evaluation and care coordination near Mineola, Garden City, Westbury, and nearby Nassau County communities. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Manhattan
StuyTown
259 1st Ave, New York, NY 10003
A place to begin evaluation and care coordination near StuyTown, the East Village, Gramercy, and nearby Manhattan neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Brooklyn
Williamsburg
308 Graham Ave, Brooklyn, NY 11211
A place to begin evaluation and care coordination near Williamsburg, Greenpoint, Bushwick, and nearby Brooklyn neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Related care and next steps
Use these focused pages to compare options, prepare for an evaluation, and connect medication questions with broader care.
Wegovy injection
Review broader dose, device, weight, cardiovascular, and safety questions.
Medical weight loss
Explore Nao Medical's broader weight-management program and treatment options.
Diabetes medication management
Coordinate glucose treatment when type 2 diabetes is present.
Advanced lipid testing
Address cardiovascular risk questions without making them part of the MASH diagnosis.
Primary care
Use ongoing primary care to connect medication decisions with the rest of your health history.
Frequently asked questions
Answers reflect the current official sources and the limited evaluation-and-coordination scope described on this page.
MASH is metabolic dysfunction-associated steatohepatitis, a liver disease involving fat buildup, inflammation, and injury that can lead to fibrosis and cirrhosis.
The current indication is for adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis consistent with F2 to F3 stages.
No. The MASH indication belongs to Wegovy injection, not the tablet.
The MASH indication should not be broadened to isolated steatosis or an imaging finding without the labeled disease and fibrosis context.
FDA granted the indication based on improvement in MASH and fibrosis. Continued approval may depend on confirmation of clinical benefit in an ongoing trial.
No. Nao Medical must confirm diagnostic boundaries and hepatology coordination before offering this pathway.
Bring documentation of the MASH diagnosis and fibrosis stage, liver imaging and laboratory trends, pathology or elastography when available, specialist notes, and the complete medication list.
Official sources
These sources support product identity, approval, current labeling, availability, and clinical boundaries. They do not prove Nao Medical site capability or health-plan coverage.
Wegovy prescribing information
Current injection-only MASH indication, F2 to F3 fibrosis, dose, accelerated approval, and safety information.
Open official sourceFDA approves Wegovy for MASH
Approval date, adult noncirrhotic MASH population, fibrosis stage, and accelerated approval basis.
Open official sourceOfficial Wegovy website
Current U.S. product and safety information.
Open official sourceSource and label check completed August 1, 2026. Named clinical and operations review is still pending.
Health information notice
General information only. This page is not medical advice and does not replace diagnosis, treatment, or guidance from a licensed clinician.
Content was updated August 1, 2026 from the sources cited on this page. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.